کاربرد سلول‌های بنیادی در درمان هموگلوبینوپاتی‌ها

Abstractbackground and objectiveshemoglobinopathies are heterogenic hereditary disorders in which mutations lead to abnormal production of hemoglobin chains, or change in the normal sequence of the hemoglobin amino acids. thalassemia and sickle cell anemia (sca) are the most prevalent hemoglobinopathies. patients with the above mentioned disorders often require hypertransfusion regimens. however, continued blood transfusion may contribute to iron overload and consequent organ deterioration, in addition to viral infections. the aim of this review article is to evaluate recent treatment programs regarding these disorders.materials and methodsthis paper is evaluating the newest protocols applied for the treatment of thalassemia and sca by reviewing 51 references using ebsco, elsevier, pubmed and ovid databases. resultsblood transfusion and medical treatments may improve the lifestyle or increase the lifespan of patients with hemoglobinopathies. however, hematopoietic stem cell transplantation (hsct) is presented as the only curative therapy for thalassemia and sca. on the other hand, hsct may contribute to complications such as infertility and gonadal failure, especially in women, chronic graft-versus-host disease (gvhd), and potential secondary malignancies.conclusionsin spite of the limitations and complications attributed to hsct, this method is proved to be the most effective way for treatment of hemoglobinopathies. different cells and novel strategies used to modify transplantation are introduced in this article.